TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Evaxion Biotech ( (EVAX) ) has shared an announcement.
On November 4, 2025, Evaxion Biotech announced a share capital increase following the exercise of certain investor warrants. This resulted in the issuance of 1,875,000 ordinary shares, raising the company’s share capital to nominal DKK 104,252,689. The capital increase, registered with the Danish Business Authority, reflects a cash consideration of USD 101,625. This move is part of Evaxion’s strategic efforts to strengthen its financial position and potentially enhance its market presence.
The most recent analyst rating on (EVAX) stock is a Hold with a $6.50 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
Spark’s Take on EVAX Stock
According to Spark, TipRanks’ AI Analyst, EVAX is a Neutral.
Evaxion Biotech’s overall score is driven by strong earnings call highlights, including strategic partnerships and promising clinical results. However, financial instability and valuation concerns weigh heavily, reflecting the company’s ongoing challenges in achieving profitability.
To see Spark’s full report on EVAX stock, click here.
More about Evaxion Biotech
Evaxion Biotech is a company operating in the biotechnology industry, focusing on creating advanced software for the development of novel immune therapies and vaccines.
Average Trading Volume: 1,599,481
Technical Sentiment Signal: Sell
Current Market Cap: $34.49M
For a thorough assessment of EVAX stock, go to TipRanks’ Stock Analysis page.